You have free access to this content

Cancer

Cover image for Vol. 118 Issue 4

15 February 2012

Volume 118, Issue 4

Pages 867–1173

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Communication
    7. Correspondence
    8. Expression of Concern
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Communication
    7. Correspondence
    8. Expression of Concern
    1. You have free access to this content
      Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms (pages 870–877)

      Alfonso Quintás-Cardama and Srdan Verstovsek

      Article first published online: 15 JUL 2011 | DOI: 10.1002/cncr.26359

      Janus kinase 2 (JAK2) inhibitors have demonstrated significant activity in patients with myeloproliferative neoplasms (MPNs). However, the precise role of these agents in therapeutic algorithms for MPNs as well as the potential advantages and shortcomings of JAK2 inhibitor therapy have not been clearly established. Herein, these issues are critically appraised by the authors.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Communication
    7. Correspondence
    8. Expression of Concern
    1. You have free access to this content
      Deregulated microRNAs in multiple myeloma (pages 878–887)

      Leonidas Benetatos and George Vartholomatos

      Article first published online: 11 AUG 2011 | DOI: 10.1002/cncr.26297

      MicroRNAs are known to be involved in oncogenesis and in recent years have been established as potential pathogenetic factors in myelomagenesis that interact with other factors in several pathways. These findings demonstrate their important role in multiple myeloma biology and potential therapeutic applications.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Communication
    7. Correspondence
    8. Expression of Concern
    1. Disease Site

      Breast Disease
      You have free access to this content
      DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer (pages 888–898)

      Neil K. Taunk, Sharad Goyal, Hao Wu, Meena S. Moran, Sining Chen and Bruce G. Haffty

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26352

      Node-negative, early stage breast cancer patients with high levels of DDX1 were found to have a significant improvement in local control, distant metastatic-free survival, and overall survival compared with patients with low levels of DDX1.

    2. You have free access to this content
      The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers (pages 899–907)

      Mieke Kriege, Agnes Jager, Maartje J. Hooning, Elisabeth Huijskens, Jannet Blom, Carolien H. M. van Deurzen, Marijke Bontenbal, J. Margriet Collee, Marian B. E. Menke-Pluijmers, John W. M. Martens and Caroline Seynaeve

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26351

      BRCA1-associated, hormone receptor (HRec)-negative metastatic breast cancer patients were less sensitive to taxane chemotherapy compared with sporadic HRec-negative patients. HRec-positive BRCA1- and BRCA2-associated patients had a similar sensitivity to taxane chemotherapy to sporadic patients.

    3. You have free access to this content
      Early onset HER2-positive breast cancer is associated with germline TP53 mutations (pages 908–913)

      Amal Melhem-Bertrandt, Jasmina Bojadzieva, Kaylene J. Ready, Elias Obeid, Diane D. Liu, Angelica M. Gutierrez-Barrera, Jennifer K. Litton, Olufunmilayo I. Olopade, Gabriel N. Hortobagyi, Louise C. Strong and Banu K. Arun

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26377

      Germline TP53 mutations lead to early onset breast cancer and are associated with Li-Fraumeni syndrome. There are limited data on the pathological characteristics of these cancers. In this article, we describe an association between breast cancer in patients with germline TP53 mutation and human epidermal growth factor receptor 2 overexpression.

      Corrected by:

      Erratum: Erratum: Early onset HER2-positive breast cancer is associated with germline TP53 mutations

      Vol. 118, Issue 9, 2561, Article first published online: 31 AUG 2011

    4. You have free access to this content
      Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization (pages 914–923)

      Seho Park, Hyung Seok Park, Ja Seung Koo, Woo Ick Yang, Seung Il Kim and Byeong-Woo Park

      Article first published online: 28 JUL 2011 | DOI: 10.1002/cncr.26406

      Immunohistochemistry (IHC) is highly concordant with fluorescence in situ hybridization (FISH) in the assessment of human epidermal growth factor receptor 2 (HER2), but FISH better predicts prognosis of breast cancer patients. HER2 IHC-negative tumors showing luminal B subtype features of estrogen receptor-positive, grade II/III, and high Ki-67 proliferative index are highly associated with discordant FISH-positive result.

    5. Gastrointestinal Disease
      You have free access to this content
      Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer (pages 924–936)

      Junhong Zhao, Hongchuan Jin, Kin Fai Cheung, Joanna H. M. Tong, Sui Zhang, Minnie Y. Y. Go, Linwei Tian, Wei Kang, Patrick P. S. Leung, Zhirong Zeng, Xiaoxing Li, Ka Fai To, Joseph J. Y. Sung and Jun Yu

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26184

      The authors studied the effects of zinc finger E-box binding factor 1 (ZEB1) on the latent-lytic switch of Epstein-Barr virus (EBV) infection in gastric cancer and explored the importance of EBV in gastric carcinogenesis. The results indicated that ZEB1 is a key mediator of the latent-lytic switch of EBV-associated gastric cancer, a distinct subtype with different clinicopathologic features, and ZEB1 may be a potential target for EBV-associated gastric cancer therapy.

    6. You have free access to this content
      Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer (pages 937–946)

      Feng Zhou, Xianli He, Hanqiang Liu, Yong Zhu, Tianbo Jin, Chao Chen, Falin Qu, Yunming Li, Guoqiang Bao, Zhinan Chen and Jinliang Xing

      Article first published online: 19 JUL 2011 | DOI: 10.1002/cncr.26348

      This is the first study to investigate the predictive role of single nucleotide polymorphisms (SNPs) in circadian genes for colorectal cancer (CRC) prognosis. The authors demonstrated that 2 SNPs (rs3749474 and rs1801260) in the CLOCK gene were significantly associated with CRC overall survival.

    7. You have free access to this content
      Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer (pages 947–959)

      Kin-Fai Cheung, Cleo N. Y. Lam, Kaichun Wu, Enders K. O. Ng, Wilson W. S. Chong, Alfred S. L. Cheng, Ka-Fai To, Daiming Fan, Joseph J. Y. Sung and Jun Yu

      Article first published online: 29 JUN 2011 | DOI: 10.1002/cncr.26189

      Epigenetic silencing of the RNF180 gene, a novel tumor suppressor, by promoter methylation is a common event in gastric cancer and is associated with poor outcome in gastric cancer patients.

    8. You have free access to this content
      Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer (pages 960–972)

      Yun Su, Martin Loos, Natalia Giese, Eric Metzen, Markus W. Büchler, Helmut Friess, Arno Kornberg and Peter Büchler

      Article first published online: 26 JUL 2011 | DOI: 10.1002/cncr.26344

      The objective of this study was to investigate the effect of the oxygen sensor prolyl hydroxylase-2 (PHD2) in pancreatic cancer growth and progression. The results indicated that pancreatic cancer cells bidirectionally use PHD2 signaling to regulate tumor aggressiveness, including invasiveness and metastasis.

    9. Genitourinary Disease
      You have free access to this content
      Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients (pages 973–980)

      Nazareno Suardi, Andrea Gallina, Umberto Capitanio, Andrea Salonia, Giovanni Lughezzani, Massimo Freschi, Alexander Mottrie, Patrizio Rigatti, Francesco Montorsi and Alberto Briganti

      Article first published online: 12 JUL 2011 | DOI: 10.1002/cncr.26234

      The currently used criteria for selecting patients for active surveillance performed significantly better for patients aged <70 years. The authors believe that their current results should be taken into account when deciding whether to offer active surveillance to patients with low-risk prostate cancer.

      Corrected by:

      Erratum: Erratum: Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients

      Vol. 118, Issue 9, 2560, Article first published online: 31 AUG 2011

    10. You have free access to this content
      Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design (pages 981–986)

      Darren R. Feldman, Sujata Patil, Michael J. Trinos, Maryann Carousso, Michelle S. Ginsberg, Joel Sheinfeld, Dean F. Bajorin, George J. Bosl and Robert J. Motzer

      Article first published online: 26 JUL 2011 | DOI: 10.1002/cncr.26375

      Relapsed/refractory germ cell tumor patients have a poor prognosis and limited treatment options. The identification of novel active agents (especially cytostatic drugs) may be impaired by use of response as the primary endpoint in phase 2 trials. This retrospective study provides important data on the progression-free and overall survival of this patient population when treated with ineffective agents to guide design of future phase 2 and phase 3 studies.

    11. You have free access to this content
      Hospital-level variation in the quality of urologic cancer surgery (pages 987–996)

      John L. Gore, Jonathan L. Wright, Kenn B. Daratha, Kenneth P. Roberts, Daniel W. Lin, Hunter Wessells and Michael Porter

      Article first published online: 26 JUL 2011 | DOI: 10.1002/cncr.26373

      Studies of surgical variation may identify processes of care that could affect the quality of surgical and postoperative care. The authors report that hospital-level variation confounds the inpatient care of patients with urologic cancer, most notably for length-of-stay outcomes after nephrectomy and prostatectomy.

    12. You have free access to this content
      Small renal masses progressing to metastases under active surveillance : A systematic review and pooled analysis (pages 997–1006)

      Marc C. Smaldone, Alexander Kutikov, Brian L. Egleston, Daniel J. Canter, Rosalia Viterbo, David Y. T. Chen, Michael A. Jewett, Richard E. Greenberg and Robert G. Uzzo

      Article first published online: 15 JUL 2011 | DOI: 10.1002/cncr.26369

      This pooled analysis of small renal masses under active surveillance demonstrates the indolent biology and low metastatic potential of localized tumors during an initial course of observation.

    13. Head and Neck Disease
      You have free access to this content
      Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer (pages 1007–1013)

      Jill Gilbert, Barbara Murphy, Mary S. Dietrich, Eve Henry, Richard Jordan, Ashley Counsell, Pamela Wirth, Wendell G. Yarbrough, Robert J. Slebos and Christine H. Chung

      Article first published online: 15 JUL 2011 | DOI: 10.1002/cncr.26364

      Oxaliplatin combined with pemetrexed is well tolerated and has moderate activity as an induction regimen in head and neck cancer. This regimen should be considered as a backbone for the addition of targeted agents such as cetuximab, especially in a human papillomavirus-positive population.

    14. Hematologic Malignancies
      You have free access to this content
      Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an Italian compassionate program (pages 1014–1022)

      Luca Maurillo, Adriano Venditti, Alessandra Spagnoli, Gianluca Gaidano, Dario Ferrero, Esther Oliva, Monia Lunghi, Alfonso M. D'Arco, Alessandro Levis, Domenico Pastore, Nicola Di Renzo, Alberto Santagostino, Vincenzo Pavone, Francesco Buccisano and Pellegrino Musto

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26354

      The efficacy of azacitidine for the treatment of high-risk myelodysplastic syndromes prompted an investigation into its potential role in acute myeloid leukemia (AML); therefore, the authors of this report carried out a multicenter, retrospective analysis of 82 Italian patients with AML who received azacitidine. The current results indicated that azacitidine has promise as an effective therapy for elderly patients with untreated AML who have white blood cell counts <10 × 109/L.

    15. You have free access to this content
      Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737 (pages 1023–1031)

      Kensuke Kojima, Seshagiri Duvvuri, Vivian Ruvolo, Felipe Samaniego, Anas Younes and Michael Andreeff

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26360

      Chronic lymphocytic leukemia (CLL) cells with deletions of the short arm of chromosome 17p (del[17p]) typically have loss of functional p53, rendering them refractory to chemotherapeutic agents. In this report, the authors investigate the association of del(17p) with ABT-737 sensitivity in CLL cells, and the data indicate that p53 dysfunction may lead to decreased apoptosis induction by ABT-737.

    16. Lung Disease
      You have free access to this content
      Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung (pages 1032–1039)

      Gilberto de Lima Lopes Jr., Joel E. Segel, Daniel S. W. Tan, Young K. Do, Tony Mok and Eric A. Finkelstein

      Article first published online: 26 JUL 2011 | DOI: 10.1002/cncr.26372

      The authors present the results of the first cost-effectiveness study to assess a strategy of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib in the management of patients with advanced adenocarcinoma of the lung.

    17. Melanoma
      You have free access to this content
      Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma (pages 1040–1047)

      Audrey B. Erman, Ryan M. Collar, Kent A. Griffith, Lori Lowe, Michael S. Sabel, Christopher K. Bichakjian, Sandra L. Wong, Scott A. McLean, Riley S. Rees, Timothy M. Johnson and Carol R. Bradford

      Article first published online: 19 JUL 2011 | DOI: 10.1002/cncr.26288

      This is the largest single-institution series of patients with head and neck melanoma (n = 353) to date. The authors demonstrate sentinel lymph node biopsy to be reliable (99.7% identification rate), accurate (19.7% positive sentinel lymph node biopsy rate and 4.2% false-omission rate), and strongly prognostic of survival on multivariate analysis.

    18. Neuro-Oncology
      You have free access to this content
      Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas : Treatment results on the basis of a 22-year experience (pages 1048–1054)

      Bruce E. Pollock, Scott L. Stafford, Michael J. Link, Yolanda I. Garces and Robert L. Foote

      Article first published online: 19 JUL 2011 | DOI: 10.1002/cncr.26362

      Stereotactic radiosurgery is frequently used to manage patients with residual or recurrent World Health Organization (WHO) grade II and III intracranial meningiomas. Tumors progressing despite prior external beam radiation therapy and larger tumor volume are negative predictors of tumor control and survival for patients having radiosurgery for WHO grade II and III intracranial meningiomas.

    19. Sarcoma
      You have free access to this content
      Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma (pages 1055–1061)

      Tomoki Nakamura, Akihiko Matsumine, Takao Matsubara, Kunihiro Asanuma, Astumasa Uchida and Akihiro Sudo

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26353

      The aim of this study was to determine whether circulating C-reactive protein (CRP) levels before treatment predict the overall survival and disease-free survival in soft tissue sarcoma patients. Pretreatment elevated CRP levels were found to be a poor prognostic factor for overall survival in a univariate analysis, and a poor prognostic factor for disease-free survival in a multivariate analysis for soft tissue sarcoma patients.

    20. Discipline

      Diagnostic Imaging
      You have free access to this content
      Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer (pages 1062–1074)

      Keiji Inoue, Hideo Fukuhara, Tsutomu Shimamoto, Masayuki Kamada, Tatsuo Iiyama, Mitsuhiko Miyamura, Atsushi Kurabayashi, Mutsuo Furihata, Masanobu Tanimura, Hironobu Watanabe and Taro Shuin

      Article first published online: 19 JUL 2011 | DOI: 10.1002/cncr.26378

      Regardless of the 5-aminolevulinic acid (ALA) administration route, photodynamic diagnosis (PDD) mediated by ALA (ALA-PDD) is useful in detecting endoscopic invisible lesions such as dysplasia and carcinoma in situ, avoiding an incorrect decision on adjuvant therapy. In transurethral resection of bladder tumor, additional resection under ALA-PDD could avoid insufficient resection of tumors, reducing the rate of intravesical recurrence.

    21. Disparities Research
      You have free access to this content
      Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs : Implications for future genomic research in minority populations (pages 1075–1082)

      Yash R. Patel, Katherine A. Carr, David Magjuka, Yousef Mohammadi, Edward F. Dropcho, Angela D. Reed, Marietta L. Moore, Mary Jane Waddell, Rivienne Shedd-Steele, Christopher J. Sweeney and Noah M. Hahn

      Article first published online: 15 JUL 2011 | DOI: 10.1002/cncr.26328

      Significant demographic differences exist between healthy Caucasian and African American men who choose to participate in genomic research in terms of age, annual income, education level, and marital status. These differences may be important in future recruitment strategies for genomic research study.

    22. You have free access to this content
      Exploring racial differences in outcome and treatment for metastatic colorectal cancer : Results from a large prospective observational cohort study (BRiTE) (pages 1083–1090)

      Blase N. Polite, Amy Sing, Daniel J. Sargent, Axel Grothey, Jordan Berlin, Mark Kozloff and Shibao Feng

      Article first published online: 28 JUL 2011 | DOI: 10.1002/cncr.26394

      Similar treatment leads to equivalent outcomes between African Americans and whites even in a relatively unselected predominantly community-based population. This suggests that differences in treatment received may be driving the disparities seen in population-based epidemiologic data.

    23. Epidemiology
      You have free access to this content
      Predicting US- and state-level cancer counts for the current calendar year : Part I: evaluation of temporal projection methods for mortality (pages 1091–1099)

      Huann-Sheng Chen, Kenneth Portier, Kaushik Ghosh, Deepa Naishadham, Hyune-Ju Kim, Li Zhu, Linda W. Pickle, Martin Krapcho, Steve Scoppa, Ahmedin Jemal and Eric J. Feuer

      Article first published online: 6 JAN 2012 | DOI: 10.1002/cncr.27404

      The temporal prediction for US-level and state-level cancer mortality counts are evaluated and compared. The best method is recommended to produce the cancer mortality counts for the current calendar year published in Cancer Facts & Figures.

    24. You have free access to this content
      Predicting US- and state-level cancer counts for the current calendar year : Part II: evaluation of spatiotemporal projection methods for incidence (pages 1100–1109)

      Li Zhu, Linda W. Pickle, Kaushik Ghosh, Deepa Naishadham, Kenneth Portier, Huann-Sheng Chen, Hyune-Ju Kim, Zhaohui Zou, James Cucinelli, Betsy Kohler, Brenda K. Edwards, Jessica King, Eric J. Feuer and Ahmedin Jemal

      Article first published online: 6 JAN 2012 | DOI: 10.1002/cncr.27405

      Spatiotemporal projection methods are evaluated and compared. The best method is recommended to produce the cancer incidence counts for the current calendar year published in Cancer Facts & Figures. See also pages 000-000

    25. Medical Oncology
      You have free access to this content
      Identification of spliced variants of the proto-oncogene hdm2 in colorectal cancer (pages 1110–1118)

      Zhiwei Yu, Bin Zhang, Binbin Cui, Yihui Wang, Peng Han and Xishan Wang

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26330

      The data from the current study provide the first evidence that hdm2 mRNA is frequently mutated by alternative splicing in colorectal cancer, and may play a role in colorectal tumorigenesis or cancer progression.

    26. Outcomes Research
      You have free access to this content
      Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer (pages 1119–1129)

      James D. Murphy, Daniel T. Chang, Jon Abelson, Megan E. Daly, Heidi N. Yeung, Lorene M. Nelson and Albert C. Koong

      Article first published online: 19 JUL 2011 | DOI: 10.1002/cncr.26365

      The authors evaluated the cost-effectiveness of adding modern radiotherapy regimens to the treatment of locally advanced pancreatic cancer. Combining gemcitabine with stereotactic body radiotherapy increased the clinical effectiveness beyond that of gemcitabine alone at a cost potentially considered acceptable by today's standards.

    27. Pediatric Oncology
      You have free access to this content
      Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma : A report from the Children's Oncology Group Soft Tissue Sarcoma Committee (pages 1130–1137)

      Abha A. Gupta, James R. Anderson, Alberto S. Pappo, Sheri L. Spunt, Roshni Dasgupta, Daniel J. Indelicato and Douglas S. Hawkins

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26358

      Adolescents with rhabdomyosarcoma experienced less hematologic toxicity and greater peripheral nervous system toxicity compared with younger children. Females, regardless of age, experienced more hematologic toxicity than males. Future studies examining the age-related and sex-related differences in pharmacokinetics of chemotherapy are necessary.

    28. Radiation Oncology
      You have free access to this content
      Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection (pages 1138–1144)

      Dirk Rades, Theo Veninga, Dagmar Hornung, Oliver Wittkugel, Steven E. Schild and Jan Gliemroth

      Article first published online: 14 JUL 2011 | DOI: 10.1002/cncr.26379

      This study compared neurosurgical resection followed by whole-brain irradiation (WBI) with WBI followed by radiosurgery (WBI + RS) in 152 patients with a single brain metastasis. The less invasive regimen of WBI + RS resulted in significantly better local control of the treated metastasis, whereas survival was not found to be significantly different in both groups.

    29. Translational Research
      You have free access to this content
      Nanotextured substrates with immobilized aptamers for cancer cell isolation and cytology (pages 1145–1154)

      Yuan Wan, M. Arif Iftakher Mahmood, Na Li, Peter B. Allen, Young-tae Kim, Robert Bachoo, Andrew D. Ellington and Samir M. Iqbal

      Article first published online: 15 JUL 2011 | DOI: 10.1002/cncr.26349

      A 2-fold affinity enhancement approach of using anti-epidermal growth factor receptor aptamers on nanotextured polymer substrates demonstrated greater efficiency in isolating tumor cells.

  5. Communication

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Communication
    7. Correspondence
    8. Expression of Concern
    1. You have free access to this content
      A note from history: Landmarks in history of cancer, part 3 (pages 1155–1168)

      Steven I. Hajdu

      Article first published online: 12 JUL 2011 | DOI: 10.1002/cncr.26320

      Major events that took place between 1761 and 1863 are described and illustrated.

  6. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Communication
    7. Correspondence
    8. Expression of Concern
    1. You have free access to this content
    2. You have free access to this content
      Unclear methods in estimate of screening effect in women ages 40 to 49 years (page 1170)

      Karsten Juhl Jørgensen and Peter C. GYøtzsche

      Article first published online: 15 JUL 2011 | DOI: 10.1002/cncr.26175

    3. You have free access to this content
      Author reply (pages 1170–1171)

      Barbro Numan Hellquist, Håkan Jonsson and Lennarth Nyström

      Article first published online: 15 JUL 2011 | DOI: 10.1002/cncr.26170

      The comments of Dr. Weedon-Fekjaer, Dr. Jørgensen, and Dr. Gøtzsche are adressed.

    4. You have free access to this content
    5. You have free access to this content
  7. Expression of Concern

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Communication
    7. Correspondence
    8. Expression of Concern
    1. You have free access to this content
      Expression of concern (page 1173)

      Fadlo R. Khuri and Raphael E. Pollock

      Article first published online: 4 JAN 2012 | DOI: 10.1002/cncr.26658

SEARCH

SEARCH BY CITATION